Save the date: Orexo to host R&D Day on March 24

Uppsala, Sweden – February 4, 2026 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOF), today announces that the company will host an R&D Day for investors, analysts and media at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden, on March 24, 2026. The program will start at 9.30 am, with registration beginning at 9 am, and will end at 12 pm CET, followed by lunch.

CEO Nikolaj Sørensen and the management team will provide insights into the company’s updated strategic direction and priorities following the divestment of Zubsolv® on the US market. There will also be a presentation of the science and innovation behind the AmorphOX® technology, including ongoing development programs, differentiation potential, and target markets.

The day will also include a discussion with a selected guest speaker about the rise of alpha‑2 agonists like xylazine and their impact on overdose reversals, underscoring the unmet need behind OX390 development program.

A formal invitation with a complete program will be sent out later. To register for the event, please use below link: https://www.orexo.se/rnd-day2026

For further information:
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00, +46 73 064 16 36
E-mail: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.

For more information please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was submitted for publication at 9.30 am CET on February 4, 2026.